Richards, Merrill & Peterson, Inc. Scynexis Inc Transaction History
Richards, Merrill & Peterson, Inc.
- $191 Billion
- Q4 2024
A detailed history of Richards, Merrill & Peterson, Inc. transactions in Scynexis Inc stock. As of the latest transaction made, Richards, Merrill & Peterson, Inc. holds 110 shares of SCYX stock, worth $122. This represents 0.0% of its overall portfolio holdings.
Number of Shares
110Holding current value
$122% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SCYX
# of Institutions
53Shares Held
12.7MCall Options Held
9KPut Options Held
0-
Federated Hermes, Inc. Pittsburgh, PA2.9MShares$3.21 Million0.01% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$2.48 Million0.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.66MShares$1.84 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.23MShares$1.36 Million0.16% of portfolio
-
Amh Equity LTD626KShares$694,9170.79% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $36.2M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...